Literature DB >> 2847285

Antiviral activity and mechanism of action of ganciclovir.

T Matthews1, R Boehme.   

Abstract

Ganciclovir (9-[(1,3-dihydroxy-2-propoxy)methyl]guanine) is a potent inhibitor of viruses of the herpes family, including cytomegalovirus (CMV), that are pathogenic for humans and animals. The primary mechanism of ganciclovir action against CMV is inhibition of the replication of viral DNA by ganciclovir-5'-triphosphate (ganciclovir-TP). This inhibition includes a selective and potent inhibition of the viral DNA polymerase. Ganciclovir is metabolized to the triphosphate form by primarily three cellular enzymes: (1) a deoxyguanosine kinase induced by CMV-infected cells; (2) guanylate kinase; and (3) phosphoglycerate kinase. Other nucleotide-metabolizing enzymes may be involved as well. The selective antiviral response associated with ganciclovir treatment is achieved because of the much weaker inhibition of cellular DNA polymerases by ganciclovir-TP. Activity and selectivity are also amplified by the accumulation of ganciclovir-TP in CMV-infected cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2847285     DOI: 10.1093/clinids/10.supplement_3.s490

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  71 in total

Review 1.  Gene therapy for mesothelioma.

Authors:  Anil Vachani; Edmund Moon; Steven M Albelda
Journal:  Curr Treat Options Oncol       Date:  2011-06

2.  Effect of six virustatic nucleoside analogues on the development of fetal rat thymus in organ culture.

Authors:  M Foerster; U Kastner; R Neubert
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

3.  Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.

Authors:  R Snoeck; G Andrei; D Schols; J Balzarini; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

4.  Continuous microspectrophotometric measurement of DNA polymerase activity: application to the Klenow fragment of Escherichia coli DNA polymerase I and human immunodeficiency virus type 1 reverse transcriptase.

Authors:  J G Baillon; N T Nashed; J M Sayer; D M Jerina
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

Review 5.  Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients.

Authors:  Risto S Cvetković; Keri Wellington
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Cidofovir: a novel antitumor agent for glioblastoma.

Authors:  Piotr Hadaczek; Tomoko Ozawa; Liliana Soroceanu; Yasuyuki Yoshida; Lisa Matlaf; Eric Singer; Estefania Fiallos; C David James; Charles S Cobbs
Journal:  Clin Cancer Res       Date:  2013-10-29       Impact factor: 12.531

7.  New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

8.  Bicistronic vector for combined expression of the HSVtk killer gene and cytokine GM-CSF gene in cancer cells.

Authors:  I V Alekseenko; E P Kopantzev; T V Vinogradova; E D Sverdlov
Journal:  Dokl Biochem Biophys       Date:  2011 Jul-Aug       Impact factor: 0.788

9.  Combination gene therapy for liver metastasis of colon carcinoma in vivo.

Authors:  S H Chen; X H Chen; Y Wang; K Kosai; M J Finegold; S S Rich; S L Woo
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

10.  Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study.

Authors:  H B Hoh; C Hurley; C Claoue; M Viswalingham; D L Easty; P Goldschmidt; L M Collum
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.